Page last updated: 2024-08-26

sr141716 and Depression

sr141716 has been researched along with Depression in 33 studies

Research

Studies (33)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (72.73)	29.6817
2010's	9 (27.27)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Stavreva, GT; Tashev, RE; Velikova, MS	1
Butler, P; Munafò, MR; Nutt, DJ; Robinson, ES; Stuart, SA	1
Baldaia, MA; Berro, LF; Frussa-Filho, R; Hollais, AW; Longo, BM; Marinho, EA; Oliveira-Lima, AJ; Patti, CL; Santos, R; Takatsu-Coleman, AL; Wuo-Silva, R; Yokoyama, TS	1
Antoniou, K; Delis, F; Gueye, AB; Laviolette, SR; Le Foll, B; Loureiro, M; Makriyannis, A; Poulia, N; Pryslawsky, Y; Trigo, JM; Vemuri, K	1
Joca, SRL; Kirkedal, C; Liebenberg, N; Moreira, F; Wegener, G	1
Kapoor, S	1
Chaput, JP; Tremblay, A	1
Soyka, M	1
Aronne, LJ; Davis, SN; Foster, GD; Pagotto, U	1
Faludi, G; Halmy, L; Purebl, G; Rihmer, Z	1
Gorzalka, BB; Hill, MN	1
Kim, DH; Lee, S; Ryu, JH; Yoon, SH	1
Browning, M; Cowen, PJ; Di Simplicio, M; Harmer, CJ; Horder, J	1
Assareh, N; ElBatsh, MM; Kendall, DA; Marsden, CA	1
Boggs, DL; Buchanan, RW; Conley, RR; Gold, JM; Gorelick, DA; Huestis, MA; Kelly, DL; Linthicum, J; Liu, F; McMahon, RP; Waltz, J	1
Elbatsh, MM; Kendall, DA; Marsden, CA; Moklas, MA	1
Borrelli, F; Capasso, F; Capasso, R; Izzo, AA; Mascolo, N	1
Griebel, G; Scatton, B; Stemmelin, J	1
Gadde, KM	1
Roberfroid, D	1
Cahill, K; Ussher, M	2
Holsboer, F; Lutz, B; Marsicano, G; Nestler, EJ; Steiner, MA; Wotjak, CT	1
Mitchell, PB; Morris, MJ	1
Astrup, A; Bartels, EM; Bliddal, H; Christensen, R; Kristensen, PK	1
Boekholdt, SM; Jukema, JW; Peters, RJ	1
Cohen, AF; Dubois, EA; Pijl, H; van Bronswijk, H	1
Nau, JY	1
Al-Zaman, Y; Aylwin, S	1
Forslund, T; Hjemdahl, P; Raaschou, P; Wettermark, B	1
Després, JP; Pi-Sunyer, X; Scheen, A; Van Gaal, L	1
Blüher, M	1
Di Marzo, V; Szallasi, A	1

Reviews

7 review(s) available for sr141716 and Depression

Article	Year
Rimonabant and depression. Pharmacopsychiatry, 2008, Volume: 41, Issue:5 Topics: Alcoholism; Animals; Depression; Humans; Piperidines; Pyrazoles; Rimonabant	2008
[Association of obesity and depression]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2008, Volume: 10, Issue:4 Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disorder; Circadian Rhythm; Cyclobutanes; Depression; Depressive Disorder, Major; Dietary Carbohydrates; Energy Intake; Ghrelin; Humans; Hypothalamo-Hypophyseal System; Insulin Resistance; Leptin; Obesity; Piperidines; Pituitary-Adrenal System; Pyrazoles; Rimonabant; Seasonal Affective Disorder; Sleep Wake Disorders; Surveys and Questionnaires; Weight Gain; Weight Loss	2008
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. The Cochrane database of systematic reviews, 2007, Jul-18, Issue:3 Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking Cessation; Smoking Prevention; Suicide	2007
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. The Cochrane database of systematic reviews, 2007, Oct-17, Issue:4 Topics: Adult; Body Weight; Depression; Humans; Nausea; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Receptor, Cannabinoid, CB1; Rimonabant; Secondary Prevention; Smoking; Smoking Cessation; Smoking Prevention; Suicide	2007
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600 Topics: Anti-Obesity Agents; Anxiety Disorders; Depression; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Weight Loss	2007
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant]. Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47 Topics: Cardiovascular Diseases; Depression; Diet, Reducing; Humans; Lipids; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
Emerging concepts in the medical and surgical treatment of obesity. Frontiers of hormone research, 2008, Volume: 36 Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide	2008

Trials

3 trial(s) available for sr141716 and Depression

Article	Year
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:1 Topics: Adult; Anxiety Disorders; Depression; Emotions; Female; Humans; Male; Memory, Short-Term; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Recognition, Psychology; Rimonabant; Young Adult	2012
Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophrenia research, 2012, Volume: 134, Issue:2-3 Topics: Adolescent; Adult; Analysis of Variance; Cannabinoid Receptor Antagonists; Cognition Disorders; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Piperidines; Psychiatric Status Rating Scales; Pyrazoles; Rimonabant; Schizophrenia; Treatment Outcome; Young Adult	2012
Depression and anxiety with rimonabant. Lancet (London, England), 2007, Nov-17, Volume: 370, Issue:9600 Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Meta-Analysis as Topic; Piperidines; Pyrazoles; Rimonabant	2007

Other Studies

23 other study(ies) available for sr141716 and Depression

Article	Year
Subchronic Central Administration of Cannabinoid Ligands Modulates Nociception in Bulbectomized Rats. Folia medica, 2019, 12-31, Volume: 61, Issue:4 Topics: Animals; Depression; Disease Models, Animal; Dronabinol; Ligands; Male; Nociception; Olfactory Bulb; Pain Threshold; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant	2019
A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013, Volume: 38, Issue:9 Topics: Affect; Animals; Antidepressive Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Carbolines; Depression; Discrimination Learning; Disease Models, Animal; Environment; Isotretinoin; Male; Piperidines; Pyrazoles; Rats; Reward; Rimonabant; Stress, Psychological; Translational Research, Biomedical	2013
Effects of rimonabant on the development of single dose-induced behavioral sensitization to ethanol, morphine and cocaine in mice. Progress in neuro-psychopharmacology & biological psychiatry, 2015, Apr-03, Volume: 58 Topics: Akathisia, Drug-Induced; Animals; Animals, Outbred Strains; Anxiety; Cannabinoid Receptor Antagonists; Central Nervous System Depressants; Cocaine; Depression; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Ethanol; Male; Mice; Morphine; Motor Activity; Narcotics; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders	2015
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:12 Topics: Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Cannabinoid Receptor Antagonists; Cues; Depression; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Inverse Agonism; Drug-Seeking Behavior; Male; Maze Learning; Mesencephalon; Motivation; Motor Activity; Piperidines; Pyrazoles; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Swimming; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Weight Loss	2016
A dual inhibitor of FAAH and TRPV1 channels shows dose-dependent effect on depression-like behaviour in rats. Acta neuropsychiatrica, 2017, Volume: 29, Issue:6 Topics: Amidohydrolases; Animals; Antidepressive Agents; Arachidonic Acids; Behavior, Animal; Cannabinoid Receptor Antagonists; Depression; Dose-Response Relationship, Drug; Drug Inverse Agonism; Male; Piperidines; Prefrontal Cortex; Pyrazoles; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin; TRPV Cation Channels	2017
Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome. Clinical endocrinology, 2009, Volume: 70, Issue:2 Topics: Cannabinoid Receptor Antagonists; Depression; Female; Humans; Metabolic Diseases; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant	2009
Depression and weight loss: opposite outcome for surgery and rimonabant? Obesity reviews : an official journal of the International Association for the Study of Obesity, 2008, Volume: 9, Issue:5 Topics: Anti-Obesity Agents; Depression; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Safety; Treatment Outcome; Weight Loss	2008
The endocannabinoid system as a target for obesity treatment. Clinical cornerstone, 2008, Volume: 9, Issue:1 Topics: Amides; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Cyclobutanes; Depression; Endocannabinoids; Humans; Lactones; Life Style; Metabolic Syndrome; Obesity; Orlistat; Piperidines; Pyrazoles; Pyridines; Rimonabant; Risk	2008
Impairments in endocannabinoid signaling and depressive illness. JAMA, 2009, Mar-18, Volume: 301, Issue:11 Topics: Affect; Anti-Obesity Agents; Antidepressive Agents; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Depression; Depressive Disorder; Endocannabinoids; Humans; Ligands; Obesity; Piperidines; Pyrazoles; Research; Rimonabant; Signal Transduction; Tobacco Use Disorder	2009
Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus. Neuroscience letters, 2009, Dec-25, Volume: 467, Issue:2 Topics: Animals; Anti-Obesity Agents; Behavior, Animal; Bromodeoxyuridine; Cell Count; Depression; Doublecortin Domain Proteins; Doublecortin Protein; Hippocampus; Immunohistochemistry; Male; Mice; Mice, Inbred ICR; Microtubule-Associated Proteins; Neurogenesis; Neurons; Neuropeptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological	2009
The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat. Pharmacology, biochemistry, and behavior, 2012, Volume: 100, Issue:3 Topics: Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP Response Element-Binding Protein; Depression; Drug Inverse Agonism; Frontal Lobe; Male; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Phosphorylation; Piperidines; Protein Processing, Post-Translational; Pyrazoles; Random Allocation; Rats; Rats, Inbred Strains; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Tranylcypromine	2012
Antidepressant-like effects of Δ⁹-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression. Pharmacology, biochemistry, and behavior, 2012, Volume: 102, Issue:2 Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Depression; Disease Models, Animal; Dronabinol; Frontal Lobe; Hippocampus; Male; MAP Kinase Signaling System; Olfactory Bulb; Piperidines; Pyrazoles; Rats; Rimonabant	2012
Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro. Urology, 2004, Volume: 64, Issue:1 Topics: Acetylcholine; Adenosine Triphosphate; Animals; Anthracenes; Antidepressive Agents; Atropine; Bridged Bicyclo Compounds; Capsaicin; Depression; Electric Stimulation; Female; Haloperidol; Hypericum; Kaempferols; Male; Methysergide; Muscle Contraction; Muscle, Smooth; Naloxone; Perylene; Phentolamine; Phloroglucinol; Piperidines; Plant Extracts; Propranolol; Pyrazoles; Quercetin; Rats; Rats, Wistar; Rimonabant; Rutin; Terpenes; Tetrodotoxin; Urinary Bladder; Urinary Incontinence; Verapamil	2004
Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological psychiatry, 2005, Feb-01, Volume: 57, Issue:3 Topics: Aggression; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Depression; Diazepam; Dose-Response Relationship, Drug; Electroshock; Emotions; Fluoxetine; Gerbillinae; Immobility Response, Tonic; Male; Maze Learning; Mice; Models, Animal; Neuropsychological Tests; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant	2005
Effect of rimonabant on weight and cardiometabolic risk factors. JAMA, 2006, Aug-09, Volume: 296, Issue:6 Topics: Anti-Obesity Agents; Anxiety; Depression; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Risk Factors	2006
Rimonabant in obese patients with type 2 diabetes. Lancet (London, England), 2007, Feb-17, Volume: 369, Issue:9561 Topics: Depression; Diabetes Mellitus, Type 2; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss	2007
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice. Psychoneuroendocrinology, 2008, Volume: 33, Issue:1 Topics: Adaptation, Psychological; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Corticosterone; Depression; Desipramine; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Statistics, Nonparametric; Stress, Psychological; Swimming; Time Factors	2008
[New drugs; rimonabant]. Nederlands tijdschrift voor geneeskunde, 2007, Nov-24, Volume: 151, Issue:47 Topics: Appetite Regulation; Cardiovascular Diseases; Depression; Diet, Reducing; Energy Intake; Humans; Lipids; Lipogenesis; Obesity; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Loss	2007
[Antiobesity drugs--new limitations]. Revue medicale suisse, 2007, Nov-28, Volume: 3, Issue:135 Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Depression; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lactones; Obesity, Morbid; Orlistat; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Suicide; Weight Loss	2007
[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects]. Lakartidningen, 2007, Dec-19, Volume: 104, Issue:51-52 Topics: Anti-Obesity Agents; Cannabinoid Receptor Antagonists; Depression; Drug Approval; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Weight Loss	2007
Efficacy and safety of the weight-loss drug rimonabant. Lancet (London, England), 2008, Feb-16, Volume: 371, Issue:9612 Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Patient Selection; Piperidines; Pyrazoles; Rimonabant; Suicide	2008
Efficacy and safety of the weight-loss drug rimonabant. Lancet (London, England), 2008, Feb-16, Volume: 371, Issue:9612 Topics: Anti-Obesity Agents; Depression; Depressive Disorder, Major; Humans; Obesity; Piperidines; Pyrazoles; Rimonabant	2008
Rimonabant in rats with a metabolic syndrome: good news after the depression. British journal of pharmacology, 2008, Volume: 154, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Body Weight; Depression; Disease Models, Animal; Inflammation Mediators; Leukocytes; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant	2008